Addressing these questions may allow us to develop new strategies to rescue defective antibody responses in CD40-deficient mouse model or human PID patients, and to better treat autoimmunity or B cell lymphoma by modulating BCR signaling pathways. This evidence concerns the gene BCR and pelvic inflammatory disease.